Purpose Virus-like particles (VLPs) have been used as drug carriers for drug delivery systems. In this study, hCC49 single chain fragment variable (scFv)-displaying Rous sarcoma viruslike particles (RSV VLPs) were produced in silkworm larvae to be a specific carrier of an anti-cancer drug. Method RSV VLPs displaying hCC49 scFv were created by the fusion of the transmembrane and cytoplasmic domains of hemagglutinin from influenza A (H1N1) virus and produced in silkworm larvae. The display of hCC49 scFv on the surface of RSV VLPs was confirmed by enzyme-linked immunosorbent assay using tumor-associated glycoprotein-72 (TAG-72), fluorescent microscopy, and immunoelectron microscopy. Fluorescein isothiocyanate (FITC) or doxorubicin (DOX) was incorporated into hCC49 scFv-displaying RSV VLPs by electroporation and specific targeting of these VLPs was investigated by fluorescent microscopy and cytotoxicity assay using LS174T cells. Results FITC was delivered to LS174T human colon adenocarcinoma cells by hCC49 scFv-displaying RSV VLPs, but not by RSV VLPs. This indicated that hCC49 scFv allowed FITC-loaded RSV VLPs to be delivered to LS174T cells. DOX, which is an anti-cancer drug with intrinsic red fluorescence, was also loaded into hCC49 scFv-displaying RSV VLPs by electroporation; the DOX-loaded hCC49 scFvdisplaying RSV VLPs killed LS174T cells via the specific delivery of DOX that was mediated by hCC49 scFv. HEK293 cells were alive even though in the presence of DOX-loaded hCC49 scFv-displaying RSV VLPs. Conclusion These results showed that hCC49 scFvdisplaying RSV VLPs from silkworm larvae offered specific drug delivery to colon carcinoma cells in vitro. This scFvdisplaying enveloped VLP system could be applied to drug and gene delivery to other target cells. 
INTRODUCTION
Virus-like particles (VLPs) derived from various viruses have been utilized for vaccines, as well as gene and drug delivery systems. VLPs have nearly the same properties as intact viruses, but they have no genomic DNA or RNA that encodes viral proteins. Therefore, safety concerns related to the use of inactivated or attenuated viruses can be mitigated, especially for in vivo applications of VLPs. Additionally, VLPs have empty interior space in which various materials, drugs, nucleic acids, and nanoparticles can be loaded for gene and drug delivery (1, 2) . Non-enveloped VLPs can be produced through the expression of a viral capsid protein. Expressed capsids are self-assembled and form VLPs. These VLPs sometimes have nucleic acids derived from host cells, but the nucleic acids can be removed by the disassembly of VLPs. The disassembly and reassembly of VLPs ensures a uniform size of VLPs (3) . Enveloped VLPs have a lipid membrane and an envelope that are derived from host cells when the VLPs self-assemble and bud from host cells. When enveloped VLPs are expressed simultaneously with membrane proteins, the membrane proteins are embedded into the envelope of VLPs during the budding process (2) .
VLPs can be functionalized through various methods to provide specificity as nanoparticles. The surface and the interior of VLPs can be specialized for functions including cell specificity, display of immunological antigens, and stabilization by chemical and genetic modification. The surface of non-enveloped VLPs can be functionalized by a covalent approach through amino acid residues on the surface, including lysine, cysteine, and others (4) . This covalent modification is an irreversible reaction, which is favorable for long-term binding to targets. Alternatively, peptides and proteins can be displayed on the surface of non-enveloped VLPs by using a fusion technique with virus capsid proteins. Enveloped VLPs can also be functionalized chemically and genetically through the modification of envelope proteins. The fusion of a foreign protein with a full-length or transmembrane domain of a viral envelope protein enables its protein to be displayed on the surface of enveloped VLPs (5, 6) . Additionally, foreign transmembrane proteins can be displayed on enveloped VLPs by their co-expression in hosts, which allows for multifunctional VLPs (1, 7) .
Recently, Rous sarcoma virus (RSV) VLPs displaying a scFv of humanized CC49 antibody (hCC49) were produced in silkworm larvae in order to target the specific delivery of drugs to colon carcinoma cells (8) . In this case, hCC49 scFv was linked by glycosylphosphatidylinositol (GPI) anchor on the surface of RSV VLPs. These particles specifically delivered sulforhodamine B to colon carcinoma cells, LS174T cells. In other paper, using RSV gag protein and M1 protein from influenza A virus, chimeric VLPs were produced in silkworm larvae and applied to drug delivery system and vaccine production (9) . Modification of RSV VLPs can provide these particles various capacities.
In this study, RSV VLPs displaying hCC49 scFv by using transmembrane and cytoplasmic domains of hemmaglutinin (HA) from influenza A virus were produced in silkworm larvae for the application to drug delivery system, instead of the use of GPI anchor reported previously (8) . The hCC49 scFv binds specifically to tumor-associated glycoprotein-72 (TAG-72) on the surface of colon carcinoma cells (10, 11) . TAG-72 is also expressed very low level in human adenocarcinomas of the colon, pancreas, and breast, but it is not expressed in normal tissues (12) . Doxorubicin (DOX) was used as an anti-cancer drug to be delivered to colon carcinoma cells by hCC49 scFvdisplaying RSV VLPs.
MATERIALS AND METHODS
Cell Lines, Media, and Silkworms LS174T human colon adenocarcinoma (ATCC CL-188) and HEK293 (RCB1637) cell lines were purchased from ATCC (Manassas, VA, USA) and Riken Bio Resource Center (Tsukuba, Ibaraki, Japan), respectively. LS174T cells were cultured in 25-cm 2 T-flasks with MEM-Eagle medium (Sigma-Aldrich, St. Louis, MO, USA) containing 10% (v/v) fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and supplemented with 1% (v/v) antibiotic solution containing penicillin, streptomycin, and fungizone (Sigma-Aldrich). The cultures were placed in an incubator (MCO-175 Sanyo, Osaka, Japan) maintained at 37°C with 5% CO 2 . HEK293 cells were cultured in 25-cm 2 T-flasks with MEM/EBSS medium (HyClone Laboratories Inc., Utah, USA) containing 2 mM L-glutamine, 1% non-essential amino acid solution (Invitrogen), and 10% fetal bovine serum and supplemented with 1% (v/v) antibiotic solution containing penicillin, streptomycin, and fungizone. The cultures were placed in an incubator maintained at 37°C with 5% CO 2 .
Molting fourth instars of silkworm larvae were purchased from Ehimesansyu (Yahatahama, Ehime, Japan). Silkworm larvae were reared on an artificial diet of Silkmate 2S (Nihon Nosan Kogyo, Yokohama, Japan) in a 60% humidity chamber (MLR-351H, Sanyo, Tokyo, Japan) maintained at 25°C.
Construction of Recombinant Bacmids
The construction of the Bombyx mori nucleopolyhedrovirus (BmNPV) bacmid for the expression of the RSV gag protein (BmNPV/RSV-gag-577) was described previously (13) . The scFv of hCC49 was amplified by PCR using Eco-bx-FLAGhCC49scFv and scFv-spe primers (Table I) with pROXFL92amber (hCC49) (kindly donated by Professor Hiroshi Ueda, Tokyo Institute of Technology) as a template. Also, the C-terminal domain of HA was amplified by PCR using Spe-H1N1 and H1N1-Hind primers (Table I) with Influenza A (H1N1, A/New Caledonia/20/99) HA cDNA clone (Sino Biological Inc., Beijing, China) as a template. The scFv fragments were digested by EcoRI and SpeI, and the C-terminal domain of HA was digested by SpeI and HindIII. The digested fragments were ligated into the EcoRI−HindIII site in the pFastBac1 vector. The constructed vector was transformed into E. coli BmDH10Bac (14) . The recombinant BmNPV (BmNPV/hCC49-scFv) bacmid was extracted from a white transformant.
Production and Purification of RSV VLPs in Silkworm Larvae
Each recombinant BmNPV bacmid was mixed in a 1:1 ratio with a total of 10 μg DNA. The bacmid mixture was then mixed with 1/10 volume of DMRIE-C reagent (Life Technologies Japan, Tokyo, Japan) and incubated at room temperature for 30 min. This mixture was injected into the fifth instars of silkworm larvae and these larvae were reared for 6 to 7 days. Hemolymph was collected from bacmid-injected larvae and 1-phenyl-2-thiourea (5 mM) was added to the collected hemolymph. The hemolymph was diluted with phosphate-buffered saline (PBS, pH 7.4) and loaded onto a 25% sucrose cushion; it then was centrifuged to collect VLPs. Pelleted VLPs were suspended with PBS by brief sonication. Sucrose density gradient centrifugation (25-60%) was performed to obtain the VLPs. The top (0.5 ml) fraction was collected from each sample; a total of 10 fractions were collected. These fractions containing VLPs were dialyzed with PBS using a dialysis membrane with a molecular weight cutoff of 300 kDa (Spectrum Japan, Shiga, Japan).
Protein Concentration Measurement and Western Blot
Protein concentration was measured using the Reducing Agent Compatible version of the BCA Protein Assay (Thermo Fisher Scientific, Rockford, IL, USA). SDS-PAGE and western blot were conducted as described in previous papers (13) . For the western blot, mouse anti-FLAG M2 antibody (SigmaAldrich) or mouse anti-DYKDDDDK tag antibody (Wako Pure Chemical Industries, Osaka, Japan) was used as the primary antibody to detect hCC49 scFv. Sheep anti-mouse IgG antibody (GE healthcare Japan, Tokyo, Japan) was also used as a secondary antibody.
Enzyme-linked Immunosorbent Assay
For the enzyme-linked immunosorbent assay (ELISA), TAG-72 antigen from human fluids (Sigma-Aldrich) diluted to 10 U/ml with PBS was loaded into each well of a 96-well plate. Bovine serum albumin (BSA) dissolved with PBS to a final concentration of 10 μg/ml was used as a negative control. The plates were blocked with 2% skimmed milk dissolved with PBS at room temperature for 2 h. Each well was washed three times with PBS and then samples diluted with 2% skimmed milk were added into each well; the plate was then incubated at room temperature for 1 h. Each well was washed three times with PBS and then horseradish peroxidase (HRP)-conjugated anti-FLAG M2 antibody (Sigma-Aldrich) diluted 5000-fold with 2% skimmed milk was added. The plate was incubated at room temperature for 1 h and washed with PBS. Then, the HRP reaction was performed to measure absorbance at 450 nm in each well.
Immunogold-labeling in Transmission Electron Microscopy and Dynamic Light scattering (DLS) measurement
The hCC49 scFv-displaying RSV VLPs were placed on carbon grids (Okenshoji, Tokyo, Japan) and dried at room temperature. The grids were blocked with 4% BSA for 1 h and washed with PBS. The grids were incubated with 100 folddiluted mouse anti-DYKDDDDK monoclonal antibody (Wako) for 2 h and then washed with PBS. The grids were then incubated with 200-fold diluted goat polyclonal antimouse IgG+IgM (H+L) conjugated with 10-nm gold particles (BB International, Cardiff, UK) for 2 h and washed with PBS. Negative staining was performed using 2% phosphotungstic acid and VLPs were observed using a transmission electron microscope (JEM2100F-TEM, JEOL, Tokyo, Japan). For DLS measurement, the samples were loaded onto disposable cuvettes (DTS-1061) for the measurement of size with the Zetasizer Nano series (Malvern, Worcestershire, United Kingdom).
Loading Fluorescein isothiocyanate (FITC) and DOX into RSV VLPs FITC, a fluorescent material, and DOX, an anti-cancer drug, were used as loading compounds. To load these materials into RSV VLPs, 100 μg/ml FITC or 50 μg/ml DOX were mixed with 0.5 mg of protein/ml RSV VLPs and this mixture was electroporated using the Gene Pulser Xcell system (BIO-RAD, Hercules, CA, USA) (250 V, 750 μF). After electroporation, the mixture was cooled on ice, dialyzed, and concentrated with Amicon Ultra centrifugal filters with a membrane nominal molecular weight limit of 30 kDa (Merck Millipore, Billerica, MA, USA).
Fluorescence Microscopy
For immunofluorescence microscopy, 2000 cells of human LS174T and HEK293 cell lines were seeded onto a slide glass coated with polylysine. Cells were fixed with 10% formaldehyde for 20 min. The slide glass was washed four times with PBS and the remaining formaldehyde was removed using 50 mM NH 4 Cl. The slide glass was again washed four times with PBS and then the slide glass was blocked with 4% BSA at room temperature for 2 h. The slide glass was washed four times with PBS and then VLPs were added to cells on the slide glass and incubated at room temperature for 2 h. The slide glass was washed four times with PBS and then incubated with 5000-fold diluted mouse anti-DYKDDDDK tag monoclonal antibody (Wako) at room temperature for 1 h. The slide glass was washed four times and then 1000-fold diluted goat polyclonal anti-mouse IgG (H & L) conjugated with Alexa597 (Abcam, Tokyo, Japan) was added to the cells; the slide glass was incubated at room temperature for 1 h. Finally, the slide glass was washed four times with PBS and the cells were observed using a confocal laser scanning microscope (CLSM) (LSM 700, Carl Zeiss, Oberkochen, Germany).
For the analysis of chemical delivery, 2000 cells of human LS174T and HEK293 cell lines were seeded onto an aminosilane-coated slide glass with chambers and cultivated at 37°C for 24 h. Culture media in each chamber was discarded and VLP solution was added into each chamber. The slide glass was incubated at 37°C for 24 h and the cells were fixed with 10% formaldehyde for 20 min. The slide glass was washed three times and the remaining formaldehyde was removed with 50 mM NH 4 Cl. Finally, 4′6-diamidino-2-phenylindole was added to the cells and the stained cells were observed using CLSM. 
RESULTS

Co-expression of RSV gag Proteins and hCC49 scFv in Silkworm Larvae
RSV gag protein was expressed in silkworm larvae and formed successfully enveloped VLPs in the hemolymph of silkworm larvae (13) . The hCC49 scFv was displayed on the surface of RSV VLPs that specifically targeted colon adenocarcinoma cells. To display this scFv on the VLPs, the C-terminal domain of HA from Influenza A (H1N1), which contains its transmembrane and cytoplasmic domains, was fused at the C-terminus of scFv (Fig. 1) . The recombinant BmNPV bacmid harboring these genes under the polyhedrin promoter was constructed. Using BmNPV/RSV-gag-577 and BmNPV/hCC49-scFv bacmids, the gag protein of RSV and hCC49 scFv were coexpressed in silkworm larvae. The gag protein of RSV has been expressed and processed in various forms (13, 15) . Most of the RSV gag protein and hCC49 scFv were expressed in the fat body of silkworm larvae (Fig. 2a) . After sucrose density gradient centrifugation, RSV gag protein and hCC49 scFv were observed in the purified sample (Fig. 2b) .
Characterization of hCC49 scFv-displaying RSV VLPs
To confirm the display of hCC49 scFv on the surface of these VLPs, ELISA, immunoelectron microscopy, and immunofluorescence microscopy were performed using LS174T cells. Incubation of purified hCC49 scFv-displaying RSV VLPs with LS174T cells yielded specific fluorescence around the cells (upper panel of Fig. 3a) . However, purified RSV VLPs to LS174 cells did not provided red fluorescence around LS174T cells (lower panel of Fig. 3a) . It indicated that hCC49scFv allowed RSV VLPs to bind specifically to TAG-72 on the surface of LS174T cells. The TAG-72 expression was confirmed by western blot (Supplementary Figure 1) . In addition, ELISA revealed specific binding of these purified VLPs to TAG-72; the purified VLPs were compared to a negative control using BSA (Fig. 3b) . Gold particles were observed on the surface of purified RSV VLPs (Fig. 3c) . The average diameters of RSV VLPs and hCC49 scFv-displaying RSV VLPs were approximately 50 and 90 nm, respectively (Fig. 3d) . These results indicated that hCC49 scFv was displayed on the surface of hCC49 scFv-displaying RSV VLPs.
Fluorescent Compound Loading and Delivery
FITC was loaded into hCC49 scFv-displaying RSV VLPs and used to model delivery to target cells. FITC was loaded into
VLPs by electroporation. LS174T cells treated with FITCloaded hCC49 scFv-displaying RSV VLPs were observed using CLSM and green fluorescence of FITC was observed inside the cells (Fig. 4) . However, only slight green fluorescence of FITC was observed in LS174T cells treated with FITC-loaded RSV VLPs. This indicated that the hCC49 scFv allowed RSV VLPs to specifically target LS174T cells and FITC was specifically delivered to these cells.
To further investigate the possibility to use hCC49 scFvdisplaying RSV VLPs for drug delivery system, DOX-loaded hCC49 scFv-displaying RSV VLPs was prepared. DOX was used as a model of an anti-cancer drug in this study. DOX causes intercalation of DNA in cancer cells, which leads to cancer cell death, but DOX has several adverse effects, including serious heart damage. Specific delivery of DOX to target cells would reduce its adverse effects. DOX can be easily Fig. 1 Schematic presentation of this study. RSV gag protein and hCC49 scFV fused with the C-terminal region of hemagglutinin from influenza A (H1N1) virus (A/duck/NY/191255-59/02) were simultaneously expressed in silkworm larvae using the BmNPV bacmid system. The hCC49 scFv-displaying RSV VLPs were obtained from collected hemolymph by sucrose density gradient centrifugation. FITC or DOX was loaded into the VLPs by electroporation. Drug delivery to colon carcinoma cells (LS174Tcells) was performed using FITC-or DOX-loaded hCC49 scFv-displaying RSV VLPs. anti-FLAG anti-FLAG (hCC49 scFv) anti-Gag measured by either fluorescent microscope or fluorescence spectrophotometer because it exhibits red fluorescence (ex. 480 nm, em. 575 nm). Approximately 14 μg/ml of DOX (10 μl) was loaded in 200 μg of protein of hCC49 scFvdisplaying RSV VLPs by electroporation (incorporation efficiency 0.7%, data not shown). LS174T cells were treated with DOX-loaded hCC49 scFv-displaying RSV VLPs and DOXloaded RSV VLPs. DOX-loaded RSV VLPs were used as a control. The cytotoxicity of these VLPs was investigated using LS174T cells and HEK293 cells. The viability of LST174T cells treated with DOX-loaded hCC49 scFv-displaying RSV VLPs decreased by 35%, but the viability of HEK293 cells treated with the same VLPs remained at 100% (Fig. 5 ). This indicated that hCC49 scFv-displaying RSV VLPs specifically recognized LS174T cells and delivered DOX to LS174T cells. Non-specific delivery of DOX to HEK293 cells was not observed. In addition, the cytotoxicity of DOX-loaded RSV VLPs to LS174T cells and HEK293 cells was not observed, which indicated that hCC49 scFv displayed on the surface of RSV VLPs recognized its antigen, TAG-72, on the surface of LS174T cells. Free DOX (10 μg/ml, total amount 0.1 μg) killed 18% LS174T cells, but DOX-loaded hCC49 scFv-displaying RSV VLPs (amount of DOX loading: 0.14 μg) have the higher cytotoxicity specific to LS174T cells (35%). It indicated that DOX-loaded hCC49 scFv-displaying RSV VLPs was more efficient to kill LS174T cells than free DOX even if the same amount of DOX loaded into hCC49 scFv-displaying RSV VLPs was used as free DOX. In this experiment, it is possible that DOX is adhered to these VLPs on the surface, not loaded inside these VLPs, and delivered to LS174T cells. To exclude this possibility, hCC49 scFvdisplaying RSV VLPs, which was purified after just mixing with 50 μg/ml DOX, were used as a control. The hCC49 scFv-displaying RSV VLPs mixed with DOX slightly killed LS174T cells (8%), but DOX-loaded hCC49 scFvdisplaying RSV VLPs killed more LS174T cells (35%). This result indicated DOX was not adhered to the surface of hCC49 scFv-displaying RSV VLPs by mixing with free DOX and was loaded to these VLPs by electroporation.
DISCUSSION
In this study, hCC49 scFv-displaying RSV VLPs were produced by the co-expression of RSV gag protein and hCC49 scFv fused with the C-terminal domain of HA in silkworm larvae. Specific delivery of DOX to LS174T cells was completed using these RSV VLPs. When RSV VLPs are prepared using BmNPV bacmid in silkworm larvae, GP64, which is a major baculoviral envelope protein, is displayed on the surface of RSV VLPs (16) . GP64 is essential for the transduction of baculoviruses into mammalian cells and is attached to the cell surface and internalized by receptor-mediated endocytosis followed by low pH-triggered membrane fusion (17) (18) (19) . The interaction of GP64 with phospholipids and cholesterol heparin mediates baculovirus internalization to mammalian cells (20) (21) (22) . In this study, hCC49 scFv displayed on the surface of RSV VLPs allowed DOX to be specifically delivered to LS174T cells (Figs. 4 and 5) . DOX was not specifically delivered to LS174T cells using RSV VLPs, even though RSV VLPs have GP64 on the surface (Figs. 4 and 5) . These results suggest that the specificity of hCC49 scFv to LS174T cells is high, which enables specific delivery of DOX to LS174T cells without its non-specific delivery via GP64. Antibodies can be also conjugated with VLPs and various nanoparticles, but, sometimes, antibodies lose ligand capacity by promiscuous conjugation with VLPs and nanoparticles. When RSV gag protein was co-expressed with hCC49 scFv fused with the C-terminal region of HA from influenza A virus, no modification steps were needed to obtain hCC49 scFv-displaying RSV VLPs in silkworms. The fusion of hCC49 scFv with the C-terminal domain of HA did not disturb its binding capacity to the antigen and its active scFv on the surface of RSV VLPs specifically bound to colon carcinoma cells, LS174T cells (Fig. 3a and b) . Antibody-display system on the surface of envelope VLPs using a heterologous transmembrane domain is useful for drug delivery to target cells. This system can be applied to the other expression systems using yeasts, insect cells and mammalian cells instead of silkworms. Especially, monoclonal antibodies against antigens specific to cancer cells have been utilized for drug delivery and tumor cell imaging because of the high specificities to ligands (23) . Monoclonal antibodies have the potential to specifically deliver drugs to targeted cells, which could minimize side effects and reduce drug doses. Among monoclonal antibodies, monoclonal scFv, which was also used in this study, is the best choice to be displayed on the surface of nanomaterials including VLPs because of its size and structure.
Several methods of loading drugs into enveloped viruses and VLPs have been reported. Electroporation enables carboxylated quantum dots to be loaded into enveloped VLPs (24) . In the case of human hepatitis B virus (HBV) particles composed of L protein, the fusion of HBV particles with liposomes containing DNA is more efficient for loading DNA than electroporation (2, 25) . In the case of hemagglutinating virus of Japan (HVJ, Sendai virus), detergent treatment, liposome fusion, and electroporation have been applied for the load of drugs, nucleic acids, and nanoparticles (24, 26, 27) . For example, detergent treatment of HVJ with centrifugation for plasmid DNA incorporation provides high loading efficiency (approximately 20%) of plasmid DNA into HVJ (28) . The loading efficiency of electroporation was 0.7% in this study, but detergent treatment with centrifugation would also be an efficient method for loading various materials, including DOX, into RSV VLPs. In addition, large unilamellar vesicles (LUV) also help DOX and anti-cancer drugs to be loaded into RSV VLPs efficiently (8, 9) . However, the use of LUV has more tedious steps than electroporation and detergent treatment.
Specific delivery of FITC and DOX to LS174T cells was shown by its fluorescence inside the cells. However, the behavior of these fluorescent materials inside the cells has been still unclear. Viruses can enter into host cells by endocytosis or membrane fusion (29, 30) . VLPs can also enter host cells through the same way as viruses. Behaviors of hCC49 scFv-displaying RSV VLPs in LS174T cells and loaded DOX were not determined yet, but DOX seems to reach to nucleus in LS174T cells because DOX-loaded hCC49 scFv-displaying RSV VLPs killed LS174 cells specifically (Fig. 5) . However, we have to analyze the internalization pathway of FITC via hCC49 scFv-displaying RSV VLPs or passive transport through lipid bilayer after its release outside the cells from these VLPs. Various endocytosis inhibitors would give the opportunities to reveal the internalization pathway. Alternatively, programmed release system of drugs in cells can carry and release drugs to specific sites in cells and provide more efficient drug delivery to target cells (31, 32) .
CONCLUSION
In this study, hCC49 scFv-displaying RSV VLPs were prepared in silkworm larvae using the BmNPV bacmid system. The C-terminal domain of HA from influenza A (H1N1) virus enabled hCC49 scFv to be anchored into the envelope of RSV VLPs. FITC or DOX was loaded into hCC49 scFvdisplaying RSV VLPs by electroporation. DOX were delivered to colon carcinoma cells (LS174T cells) by hCC49 scFvdisplaying RSV VLPs and killed LS174T cells, but delivery of DOX to the LS174T cells using DOX-loaded RSV VLPs did not confirm.
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